Skip to main content

Peer Review reports

From: Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years

Original Submission
24 Jul 2022 Submitted Original manuscript
2 Sep 2022 Reviewed Reviewer Report - Stephen R. Walsh
4 Nov 2022 Reviewed Reviewer Report
14 Nov 2022 Author responded Author comments - Mohsen Forooghizade
Resubmission - Version 2
14 Nov 2022 Submitted Manuscript version 2
18 Nov 2022 Reviewed Reviewer Report - Stephen R. Walsh
11 Jan 2023 Reviewed Reviewer Report
24 Jan 2023 Author responded Author comments - Mohsen Forooghizade
Resubmission - Version 3
24 Jan 2023 Submitted Manuscript version 3
28 Jan 2023 Author responded Author comments - Mohsen Forooghizade
Resubmission - Version 4
28 Jan 2023 Submitted Manuscript version 4
30 Jan 2023 Author responded Author comments - Mohsen Forooghizade
Resubmission - Version 5
30 Jan 2023 Submitted Manuscript version 5
10 Feb 2023 Reviewed Reviewer Report - Stephen R. Walsh
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
13 Feb 2023 Editorially accepted
24 Feb 2023 Article published 10.1186/s12879-023-08079-1

You can find further information about peer review here.

Back to article page